benzingahace 72d
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the Food and Drug Administration approved the use of its first commercially manufactured GP2 lot for the FLAMINGO-01 Phase III clinical trial.Greenwich LifeSciences stock is among today’s top performers. What’s driving GLSI stock higher?FDA Clears First Commercial GP2 Lot for Phase III TrialThe company said the FDA reviewed and approved the first commercial lot of finished GP2 vials for use in FLAMINGO-01 in the United States. The GP2 active ingredient was manufactured in an approved commercial facility in 2023, with vial filling completed in 2024, and stability programs initiated for all lots.Greenwich LifeSciences said data from the commercial manufacturing and stability ...Full story available on Benzinga.com